Lymphotoxin β receptor signalling executesHelicobacter pylori-driven gastric inflammation in a T4SS-dependent manner
Objective
Lymphotoxin β receptor (LTβR) signalling has been implicated in inflammation-associated tumour development in different tissues. We have analysed the role of LTβR and alternative NF-κB signalling in Helicobacter pylori-mediated gastric inflammation and pathology.
Design
We analysed several ligands and receptors of the alternative NF-κB pathway, RelB, p52 nuclear translocation and target genes in tissue samples of H. pylori-infected patients with different degrees of gastritis or early gastric tumours by in situ hybridisation, immunohistochemistry, Western blot and real-time PCR analyses. Molecular mechanisms involved in LTβR activation by H. pylori were assessed in vitro using human gastric cancer cell lines and distinct H. pylori isolates. The effects of blocking or agonistically activating LTβR on gastric pathology during challenge with a human pathogenic H. pylori strain were studied in a mouse model.
Results
Among the tested candidates, LT was significantly increased and activated alternative NF-κB signalling was observed in the gastric mucosa of H. pylori-infected patients. H. pyloriinduced LTβR–ligand expression in a type IV secretion system-dependent but CagA-independent manner, resulting in activation of the alternative NF-κB pathway, which was further enhanced by blocking canonical NF-κB during infection. Blocking LTβR signalling in vivo suppressed H. pylori-driven gastritis, whereas LTβR activation in gastric epithelial cells of infected mice induced a broadened pro-inflammatory chemokine milieu, resulting in exacerbated pathology.
Conclusions
LTβR-triggered activation of alternative NF-κB signalling in gastric epithelial cells executes H. pylori-induced chronic gastritis, representing a novel target to restrict gastric inflammation and pathology elicited by H. pylori, while exclusively targeting canonical NF-κB may aggravate pathology by enhancing the alternative pathway.
Top-30
Journals
|
1
2
|
|
|
Frontiers in Immunology
2 publications, 5.26%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 5.26%
|
|
|
Gut
2 publications, 5.26%
|
|
|
Helicobacter
2 publications, 5.26%
|
|
|
Future Microbiology
1 publication, 2.63%
|
|
|
Viruses
1 publication, 2.63%
|
|
|
Cancers
1 publication, 2.63%
|
|
|
Microorganisms
1 publication, 2.63%
|
|
|
Cancer Cell International
1 publication, 2.63%
|
|
|
Cellular and Molecular Life Sciences
1 publication, 2.63%
|
|
|
Cell Death and Differentiation
1 publication, 2.63%
|
|
|
Cell Death Discovery
1 publication, 2.63%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 2.63%
|
|
|
Scientific Reports
1 publication, 2.63%
|
|
|
Nature Cell Biology
1 publication, 2.63%
|
|
|
Cell Death and Disease
1 publication, 2.63%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 2.63%
|
|
|
International Journal of Medical Microbiology
1 publication, 2.63%
|
|
|
Biochemical Pharmacology
1 publication, 2.63%
|
|
|
Phytomedicine
1 publication, 2.63%
|
|
|
Biochimica et Biophysica Acta - Molecular Cell Research
1 publication, 2.63%
|
|
|
FASEB Journal
1 publication, 2.63%
|
|
|
Clinical and Experimental Pharmacology and Physiology
1 publication, 2.63%
|
|
|
EMBO Reports
1 publication, 2.63%
|
|
|
Computational and Mathematical Methods in Medicine
1 publication, 2.63%
|
|
|
BioMed Research International
1 publication, 2.63%
|
|
|
Current Topics in Microbiology and Immunology
1 publication, 2.63%
|
|
|
Medicine (United States)
1 publication, 2.63%
|
|
|
Clinical and Translational Discovery
1 publication, 2.63%
|
|
|
1
2
|
Publishers
|
2
4
6
8
10
12
|
|
|
Springer Nature
12 publications, 31.58%
|
|
|
Elsevier
6 publications, 15.79%
|
|
|
Frontiers Media S.A.
4 publications, 10.53%
|
|
|
Wiley
4 publications, 10.53%
|
|
|
MDPI
3 publications, 7.89%
|
|
|
BMJ
2 publications, 5.26%
|
|
|
Hindawi Limited
2 publications, 5.26%
|
|
|
Taylor & Francis
1 publication, 2.63%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 2.63%
|
|
|
European Molecular Biology Organization
1 publication, 2.63%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 2.63%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.63%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.